株式会社ユカリア Logo

株式会社ユカリア

Management, DX, and data solutions for healthcare and long-term care providers.

286A | T

Overview

Corporate Details

ISIN(s):
JP3946900002
LEI:
Country:
Japan
Address:
千代田区霞が関3丁目2番5号 霞が関ビルディング19階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Eucalia Inc. is a healthcare services company dedicated to transforming the medical and long-term care sectors. Its core business is providing management and operational support for hospitals and care facilities. The company offers a comprehensive suite of services, including management consulting, medical digital transformation (DX) solutions, and medical data utilization. Eucalia also directly operates facilities for the elderly. Its client base includes hospitals, care facilities, pharmaceutical companies, and academic institutions. The company operates on the principle of 'Sanpo-yoshi' (good for all three parties), aiming to build a sustainable ecosystem that improves the quality of life for facility management, healthcare workers, and patients alike, thereby strengthening the social infrastructure of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 09:21
Interim Report
確認書
Japanese 8.6 KB
2025-08-14 09:19
Interim Report
半期報告書-第21期(2025/01/01-2025/12/31)
Japanese 295.4 KB
2025-06-18 02:30
M&A Activity
臨時報告書
Japanese 20.2 KB
2025-06-05 09:46
M&A Activity
臨時報告書
Japanese 32.5 KB
2025-05-15 09:01
M&A Activity
臨時報告書
Japanese 30.0 KB
2025-05-15 07:43
M&A Activity
臨時報告書
Japanese 29.9 KB
2025-03-28 06:37
Post-Annual General Meeting Information
臨時報告書
Japanese 25.3 KB
2025-03-28 06:36
Registration Form
確認書
Japanese 8.6 KB
2025-03-28 06:36
Governance Information
内部統制報告書-第20期(2024/01/01-2024/12/31)
Japanese 23.3 KB
2025-03-28 06:35
Annual Report
有価証券報告書-第20期(2024/01/01-2024/12/31)
Japanese 2.0 MB
2025-02-17 02:05
M&A Activity
臨時報告書
Japanese 27.0 KB
2024-12-03 07:30
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.1 MB
2024-11-25 07:30
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.1 MB
2024-11-08 07:30
Registration Form
有価証券届出書(新規公開時)
Japanese 4.0 MB
2024-03-29 07:00
Foreign Filer Report
親会社等状況報告書(内国会社)-第19期(2023/01/01-2023/12/31)
Japanese 25.1 KB

Automate Your Workflow. Get a real-time feed of all 株式会社ユカリア filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社ユカリア

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社ユカリア via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.